Study details
Enrolling now
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
i-SENS, Inc.
NCT IDNCT07296276ClinicalTrials.gov data as of Apr 2026
Target enrollment
32
Study length
about 3 months
Ages
18–65
Locations
4 sites in CA, GA, WA
What this study is about
Researchers are testing the accuracy and precision of a continuous glucose monitoring (CGM) system called CareSens Air 3 in adults with type 1 diabetes. The trial will involve inserting the CGM device twice, once as the primary insertion and again as a secondary insertion. Participants will wear the CGM for 92 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use CareSens Air 3 primary insertion
- 2.Use CareSens Air 3 secondary insertion
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Endocrinology